Green Mountain Logic will unveil LabPAS/CT Version 2.5 at the DIA Annual Meeting.
Philadelphia, June 18–21, booth # 1520-Version 2.5 deploys PDAs on clinic floors to scan patient and collection vessel barcodes, eliminating the potential for errors. It provides real time electronic data entry for collection times, comments, dosing, vital signs and adverse events. LabPAS/CT 2.5 also allows integration with document management systems and with biometric systems for positive subject ID.
LabPAS/CT uses a Web interface and intuitive navigation and is the most scalable, configurable and customizable workflow and sample management solution on the market today. Through the innovative use of barcode scanning it eliminates errors, tracks samples, increases throughput, and supports compliance. In addition, sample collection and dosing are scheduled and tracked according to trial protocols. LabPAS/CT supports compliance with FDA 21 CFR Part 11, GCP and GLP, and also empowers study managers to rapidly alter workflow and schedules as protocols change, by simply dragging and dropping items on their computer screen. It was developed under Green Mountain Logic's design control process, audited and approved by multiple, nationally-recognized pharmaceutical clients. GML is in compliance with FDA guidance for the development of high-risk software systems and for development of Class 2 Medical Devices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.